GGrantIndex
Sort

23,748 grants matching melanoma

SBIR Phase I: Highly Specific Flex-Hinge Antibody-Like Checkpoint Inhibitors for Safer and More Effective Cancer Therapy

$224,455
Daniel J Capon · Hinge Bio, Inc. · · FY2018 · TIP

Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients

$224,400
Seth M Pollack · Northwestern University At Chicago · R21 · FY2023 · CA

Strategies to improve the adoptive transfer of T cells

$224,371
Stanley R Riddell · Fred Hutchinson Cancer Research Center · R01 · FY2010 · CA

Analytic and Clinical Validation of a 7-plex MIF Assay for Predictive Response of Advanced NSCLC to Anti-PD-1 based Therapy

$224,347
Janis M. Taube · Johns Hopkins University · UH2 · FY2022 · CA

Project 3: Translational Studies and Clinical Pharmacology of TLR4 and TOPK Signaling Pathway Inhibitors for Prevention of Squamous Cell Carcinoma of the Skin

$224,173
Clara Curiel-Lewandrowski · University Of Arizona · P01 · FY2022 · CA

LONG-CIRCULATING TUMOR-SELECTIVE DNA DELIVERY SYSTEMS

$224,153
Northeastern University · R01 · FY2004 · CA

Protection Against Chemotherapy-Induced Gastrointestinal Mucositis by a Sphingosi

$224,116
Charles D Smith · Apogee Biotechnology Corporation · R43 · FY2014 · DK

The Unfolded Protein Response in Melanoma Progression and Chemoresistance

$224,100
Maria S Soengas · Spanish National Cancer Center · R01 · FY2012 · CA

The Unfolded Protein Response in Melanoma Progression and Chemoresistance

$224,100
Maria S Soengas · Spanish National Cancer Center · R01 · FY2009 · CA

The Unfolded Protein Response in Melanoma Progression and Chemoresistance

$224,100
Maria S Soengas · Spanish National Cancer Center · R01 · FY2008 · CA

The Unfolded Protein Response in Melanoma Progression and Chemoresistance

$224,100
Maria S Soengas · Spanish National Cancer Center · R01 · FY2010 · CA

Mesenchymal Stromal Cells and Stromal Fibroblasts in Radiotherapy Resistance

$224,099
Guangwen Ren · Jackson Laboratory · R00 · FY2018 · CA

Breast cancer Vaccine Strategies for HER2-Overexpressing and Lum. B Tumors

$224,073
Jonathan Stuart Serody · Univ Of North Carolina Chapel Hill · P50 · FY2008 · CA

Specification, induction and development of the neural crest in rabbit embryos

$224,064
Martin Ignacio Garcia-Castro · University Of California Riverside · R21 · FY2018 · DE

Early Clinical Testing for Melanin Targeting Radio-therapeutic agent in melanoma

$223,985
John W Babich · Molecular Insight Pharmaceuticals, Inc. · R44 · FY2009 · CA

SOUTHWEST ONCOLOGY GROUP

$223,972
University Of Michigan At Ann Arbor · U10 · FY2002 · CA

Analysis of Glycomic Regulators in Melanoma Progression

$223,942
Charles J Dimitroff · Brigham And Women'S Hospital · U01 · FY2019 · CA

Development of genome-modified Xiphophorus

$223,927
Manfred Schartl · Texas State University · R21 · FY2022 · OD

Tumor microvesicle-mediated modulation of the bone microenvironment

$223,901
Evan Todd Keller · University Of Michigan At Ann Arbor · P01 · FY2019 · CA

In Vivo Imaging Facility

$223,866
Jessie Nedrow · University Of Pittsburgh At Pittsburgh · P30 · FY2021 · CA

PEPTIDE VACCINES WITH/WITHOUT GMCSF IN STAGE IV MELANOMA

$223,864
University Of Pittsburgh At Pittsburgh · R01 · FY2004 · CA

Highly Multiplexed Analysis of Solid Tumors and Liquid Tissues by Cyclic Immunofluorescence

$223,840
Eric Kaldjian · Rarecyte, Inc. · R41 · FY2018 · CA

Breast cancer Vaccine Strategies for HER2-Overexpressing and Lum. B Tumors

$223,827
Jonathan Stuart Serody · Univ Of North Carolina Chapel Hill · P50 · FY2009 · CA

Melanoma suppressing functions of carcinoma oncogene FOXQ1

$223,808
Anna Bianchi-Smiraglia · Roswell Park Cancer Institute Corp · R21 · FY2017 · CA

Statistical Methods for Analyzing Antigen Receptors Data

$223,808
Grzegorz A Rempala · Augusta University · R01 · FY2010 · CA